Close Menu

NEW YORK – 10x Genomics reported a 17 percent year-over-year increase in third quarter revenues after the close of the market on Tuesday, driven by growth in consumables revenue from its increasing base of installed instruments.

For the three months ended Sept. 30, the company reported $71.8 million in revenues, up from $61.2 million in Q3 2019 and beating the average Wall Street estimate of $61.2 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Bloomberg reports AstraZeneca may conduct another study of its candidate SARS-CoV-2 vaccine after dosing error.

Moderna is applying for an Emergency Use Authorization for its coronavirus vaccine, according to the New York Times.

The National Health Service is to conduct a trial of Grail's blood-based screening test for cancer.

In PLOS this week: somatic mutation patterns of glioblastomas among Lebanese patients, phenome-wide study using UK Biobank data, and more.